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Background: Patients’ preferences are important for shared decision making. Therefore, we investigated patients’ and urologists’
preferences for treatment alternatives for early prostate cancer (PC).
Methods: A discrete choice experiment was conducted among 150 patients who were waiting for their biopsy results, and 150
urologists. Regression analysis was used to determine patients’ and urologists’ stated preferences using scenarios based on PC
treatment modality (radiotherapy, surgery, and active surveillance (AS)), and risks of urinary incontinence and erectile dysfunction.
Results: The response rate was 110 out of 150 (73%) for patients and 50 out of 150 (33%) for urologists. Risk of urinary incontinence
was an important determinant of both patients’ and urologists’ stated preferences for PC treatment (Po0.05). Treatment modality
also influenced patients’ stated preferences (Po0.05), whereas the risk of erectile dysfunction due to radiotherapy was mainly
important to urologists (Po0.05). Both patients and urologists preferred AS to radical treatment, with the exception of patients
with anxious/depressed feelings who preferred radical treatment to AS.
Conclusion: Although patients and urologists generally may prefer similar treatments for PC, they showed different trade-offs
between various specific treatment aspects. This implies that urologists need to be aware of potential differences compared with
the patient’s perspective on treatment decisions in shared decision making on PC treatment.
The introduction of prostate specific antigen (PSA) assays in the
early 1990s dramatically improved the diagnostic capability to
detect prostate cancer (PC) at an early stage (i.e., early PC; Gillitzer
and Thuroff, 2003). Several treatments exist for early PC, some of
which (e.g. surgery and radiotherapy) may cause bowel problems,
incontinence, erectile dysfunction, and other complications.
However, in case of low-risk tumours, active surveillance (AS)
may result in a mortality rate similar to these radical treatments
(Klotz, 2006). Although AS may avoid the risk of the side effects
associated with radical treatment, anxiety and distress may increase
because patients know that they have to live with the idea of having
PC that is not radically treated (van den Bergh et al, 2010).
In an era of shared decision making, clinicians must ensure that
their patients experience minimal post-treatment decisional regret
(Aning et al, 2012). The evidence to date suggests that patients’
views and beliefs and those of their physician may not always be in
agreement (Emberton, 2010). This phenomenon is also seen
among urologists and their patients. For example, in the context of
benign prostate hyperplasia, patients with this disorder had (very)
different expectations of treatment compared with that of their
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urologists (Kim et al, 2011). Similarly, in the context of PC
treatment, studies show that urologists had considerable influence
on the choice of PC treatment, and that the treatment choice of
the patient was influenced by the hospital they visited (van
Tol-Geerdink et al, 2013). Differences in opinion on the
desirability of a specific treatment may hamper the communication
process and the outcome of shared decision making between the
urologist and patient (Montgomery and Fahey, 2001). To ensure
that patients with early PC experience minimal post-treatment
decisional regret, insight into patients’ and urologists’ preferences
for PC treatment is needed. However, (quantitative) studies
investigating and comparing patients’ and urologists’ (stated)
preferences for PC treatment alternatives are lacking.
Therefore, we aimed to investigate and compare the stated
preferences of patients and urologists for treatment for early PC.
For this, we used a discrete choice experiment (DCE). DCEs are a
quantitative approach to assess preferences for medical interven-
tions, products, or policies and have been employed across a
number of discipline areas, including marketing, environmental,
and transport economics, and are increasingly used in health care
(de Bekker-Grob et al, 2012; see ‘Discrete choice experiment’
section for more details).
MATERIALS AND METHODS
Study samples and elicitation mode. During January–November
2011, we prospectively approached 150 patients from Erasmus
University Medical Centre (Rotterdam, the Netherlands) who
participated in the Dutch part of the European Randomized Study
of Screening for Prostate Cancer (ERSPC; Schroder et al, 2012).
The ERSPC is a multicentre trial initiated in 1991 in the
Netherlands and in Belgium, with five additional European
countries (Sweden, Finland, Italy, Spain, and Switzerland) joining
between 1994 and 1998 (see Roobol and Schroder (2003) and
Schroder et al (2009) for the trial protocol).
We invited patients who had undergone a prostate biopsy after a
positive PSA test result, but who had not yet received their biopsy
result. The rationale for this was to allow to investigate the stated
preferences of patients for whom choosing between PC treatments
in real life might be (very) realistic, and to compare their stated
preferences with actual behaviour. This is an additional strength of
the present study, as external validity tests of DCE outcomes in
health care are limited (de Bekker-Grob et al, 2012).
Patients were contacted personally by a health professional on
the day they underwent prostate biopsy, that is, they had
knowledge of their abnormal PSA result but did not know the
biopsy result. They received a paper copy of the survey comprising
DCE questions, and an information letter with general and
background information about PC and PC treatment.
The second study group consisted of 150 urologists throughout
the Netherlands (all members of the Dutch Association of
Urology) who received a paper copy of the survey comprising
DCE questions by mail. Urologists who mentioned that they had
no experience in PC treatment, or were specialised in children care,
were excluded from the study. All participants (patients and
urologists) could return the questionnaire in a postage-paid
envelope that was included in the (mailing) package. In the
present study, the participation of patients and urologists was
completely voluntary; no incentives were used.
Approval for the study was obtained from the Medical Ethics
Committee, Erasmus MC, University Medical Centre Rotterdam
(MEC-2010-316).
Discrete choice experiment. In DCEs, it is assumed that a medical
intervention, such as a treatment, can be described by its
characteristics (attributes; e.g. risk of side effects; Ryan, 2004).
Those characteristics are further specified by variants of that
characteristic (attribute levels; e.g. for risk of side effects: 10, 20,
and 30%). A second assumption is that the individual’s preference
for a medical intervention is determined by the levels of those
attributes (Ryan, 2004). The relative importance of attributes and
the trade-offs that respondents make between them can be assessed
by offering a series of choices between two or more medical
intervention alternatives with different combinations of attribute
levels (Appendix I; Hensher et al, 2005).
Alternatives, attributes, and attribute levels. Nowadays, the most
widely used treatment strategies for PC are AS, radiotherapy, and
surgery; in the present study, these were considered as the
treatment alternatives. The attributes and the attribute levels of
these treatment alternatives were derived from the literature
(Stanford et al, 2000; Potosky et al, 2004; Damber and Khatami,
2005; Korfage et al, 2005; Penson et al, 2008). In addition, we
interviewed urologists and senior researchers in the field of PC
treatment to determine which treatment attributes were mostly
considered by patients and/or urologists in choosing a PC
treatment. In the interviews, we asked them to comment on and
complete the list of relevant treatment attributes/attribute levels
that was created from the literature review. On the basis of these
data, the following PC treatment attributes were determined:
permanent risk of urinary incontinence due to treatment,
permanent risk of erectile dysfunction due to treatment, risk of
other permanent side effects due to treatment (e.g., mortality risk,
bowel problems, frequent urge to urinate), frequency of PSA
testing, and treatment aim (i.e., the chance (yes/no) to physically
remove the tumour from the body). The attribute levels chosen
incorporated the range of plausible early PC treatment alternative
specific outcomes based on current literature to create realistic PC
treatment scenarios (Table 1; Appendix I); that is, curing the
disease is not the aim of AS, whereas it is for radiotherapy and
surgery; or AS more frequently required PSA testing than
radiotherapy or surgery; or the risk of urinary incontinence is
equal to or higher for surgery compared with radiotherapy.
Study design and questionnaire. The combination of the
treatment alternatives, attributes, and their levels resulted in 19
possible realistic treatment scenarios (i.e., nine different radio-
therapy scenarios; nine different surgery scenarios; and one AS
scenario). To construct choice sets for the patients, we generated an
efficient design by maximising D-efficiency (Street et al, 2005; SAS
software version 9.1, SAS Institute Inc., Cary, NC, USA). To take a
possible dominant treatment alternative into account (i.e., the
possibility that respondents always choose the same treatment
modality, irrespective of the attribute levels of the other treatment
modalities), each choice set consisted of two treatment alternatives
(i.e., AS vs a radiotherapy or surgery alternative; a radiotherapy
alternative vs a surgery alternative; or two surgery or two
radiotherapy alternatives with different attribute levels; Appendix I).
Patients were asked to consider both PC treatment alternatives
in a choice set as realistic alternatives and to choose the alternative
that was most appealing to them (i.e., the type of choice question
was a forced labelled choice set containing two PC treatments).
Twenty-four choice sets were constructed. We expected that
presenting a patient with a large number of choice sets to complete
would result in a lower response rate and/or lower response
reliability (Pearmain et al, 1991; Hall et al, 2006). As such, we
further blocked the design into two versions of questionnaires
containing 12 choice sets each (Hensher et al, 2005). For the
urologists, the same procedure was followed, except that we
generated an efficient design by maximising D-efficiency using
prior information on the basis of DCE outcomes of 70 patients to
strive for similarly reliable outcomes with a smaller sample size
(Reed Johnson et al, 2013). This procedure is a strength of the
study and does not influence the comparability between urologists’
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and patients’ stated preferences as long as the ratios between
parameters are compared (parameter ratios do have a natural
interpretation in terms of the relative importance of attributes, and
rule out a possible difference in the scale parameter; Swait and
Louviere, 1993).
Irrespective of whether the subject was a urologist or patient,
each questionnaire started with a detailed description of the
treatment modality, attributes, and their levels; that is, patients as
well as urologists received exactly the same information about PC
treatments; it contained the most relevant information about
several PC treatments including several risks of permanent urinary
incontinency and erectile dysfunction, the risk of other permanent
side effects, for example, a fixed chance of long-term bowel
problems of 5% due to radiotherapy, the main aim of the PC
treatment alternative, and the frequency of PSA testing. The central
focus of each questionnaire comprised the 12 choice sets. To keep
the choice sets understandable for respondents, we used pictures
and words alongside the specific risks of urinary incontinence and
erectile dysfunction, and used the words ‘substantial risk of’ to
present the fixed chance for long-term bowel problems (5%) and
frequent urge to urinate. An extra choice set was included that
presented all three treatment alternatives (AS, radiotherapy, and
surgery) containing the most plausible attribute levels (Appendix II).
The questionnaire also contained questions on background
variables and a question assessing experienced difficulty of the
DCE questions. The questionnaire for the patients also included a
question on generic health status (EQ-5D; including questions
about mobility, self-care, usual activity, pain, and anxiety/
depression; Dolan, 1997). (The complete questionnaire and details
on the DCE design are available from the authors on request).
The questionnaire was pilot tested (n¼ 11) to check for any
problems in interpretation and face validity; that is, using think
aloud techniques and/or debriefing the responses, insight was
obtained on (1) the understanding and complexity of the
questionnaire, (2) the time required to complete the questionnaire,
(3) the theoretical validity of the results, and (4) the completeness
of the attributes and level ranges used. The pilot test showed that
the target groups (patients and urologists) understood the choice
tasks and accurately interpreted all attributes and their levels.
Sample size. Calculation of minimum sample sizes for estimating
discrete choice models from DCE data is complicated as it depends
on the true values of the unknown parameters estimated in the
choice models (Lancsar and Louviere, 2008). Previous studies have
shown that sample sizes of 40–100 respondents may be sufficient
for reliable statistical analyses (Salkeld et al, 2005; Berchi et al,
2006; de Bekker-Grob et al, 2009). We strived to reach at least these
numbers of respondents.
Statistical analyses. The DCE was analysed by taking each choice
among two PC treatment alternatives as an observation. Using the
Nlogit software (http://www.limdep.com/), the observations were
analysed by panel-mixed logit models in error component form
(Train, 2003) to take into account the possibility of correlation
between unobserved utilities of treatment modalities (AS, surgery,
and radiotherapy), as well as the possibility of panel effects
(i.e., correlation between different choices made by the same
individual). More specifically, we allowed the constant for
‘treatment modality’ to be randomly (normally) distributed across
individuals; the s.d. of the normal distribution was estimated
together with the other parameters.
We selected the utility function with the best fit based on the
Akaike information criterion after testing a number of different
specifications for the utility (stated preference) function; for
example, categorical or numerical attribute main effects, two-way
interactions between attributes, several attribute transformations,
and interaction between treatment modality and patients’ char-
acteristics (e.g., age, educational level, household, and having
anxious/depressed feelings). As a result, the final specification of
the utility function used was:
Vradiotherapy ¼ b0þ b1urineþ b2 erectileþ b3 radiotherapyanxious
Vsurgery ¼ b4þ b5 urineþ b6 erectileþ b7 surgery anxious
VAS¼ 0
where
V represents the observable utility (stated preference score) that
a respondent has for a PC treatment scenario;
b0, b4 represent alternative specific constants for a treatment
modality (AS acts as the reference level);
b1,2, b5,6 represent alternative specific parameter weights
(or coefficients) linearly associated with the attributes ‘risk of
urinary incontinence’ and ‘risk of erectile dysfunction’;
b3, b7 represent interaction effects between patients’ character-
istic ‘anxious/depressed feelings’ and the treatment modality.
It is noteworthy that the attributes ‘risk of other permanent side
effects due to treatment’, ‘frequency of PSA testing’, and ‘treatment
aim’, all had one fixed level for each treatment modality (Table 1).
Therefore, the weights associated with these attributes are captured
in the alternative specific constants (i.e., b0 or b4).
In addition to the parameter estimates, the estimation procedure
also allows for tests of statistical significance. The statistical
significance of a coefficient (P-valuep0.05) indicated that
respondents considered the attribute important in making their
choices in the DCE. The sign of the coefficient reflects whether the
attribute has a positive or negative effect on the stated preference
score (utility).
Table 1. Attributes and alternative specific levels for prostate cancer
treatment
Attributes Alternative specific levels
Risk of urinary incontinence due to treatment (%)
Active surveillance 0
Radiotherapy 2–5–10
Surgery 10–20–30
Risk of erection problems due to treatment (%)
Active surveillance 0
Radiotherapy 15–25–35
Surgery 35–45–55
Risk of other permanent side effects due to treatment
Active surveillance No
Radiotherapy Yes, substantial risk of bowel problems and frequent
urge to urinate
Surgery Yes, small risk of mortality within 6 weeks
Main aim is cure
Active surveillance No, the tumour remains in the body
Radiotherapy Yes, but the disease may return
Surgery Yes, but the disease may return
Frequency of PSA testing with a risk of new biopsies
Active surveillance Four times in a year and at least one biopsy per year
Radiotherapy Once in a year
Surgery Once in a year
Abbreviation: PSA¼prostate specific antigen.
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We also calculated the choice probabilities for three PC
treatment modalities (i.e., AS, radiotherapy with 5% risk of
permanent urinary incontinence and 25% risk of erectile dysfunc-
tion, and surgery with 20% risk of permanent urinary incontinence
and 45% risk of erectile dysfunction), on the basis of the parameter
estimates of patients and urologists. These treatment modalities
contained the average attribute levels in the DCE. The choice
probabilities were simulated based on the panel error component
coefficients using 1000 draws from the probability density
functions estimated for the random error components. Subse-
quently, these draws were used to calculate the averages of the
choice probabilities.
Finally, using the extra choice set in the questionnaire (i.e., the
choice set with three different treatment modalities) and the
ERSPC database (i.e., data on biopsy results, the treatment advice
urologists gave to the patients, and the actual choice for PC
treatment), we directly compared the stated preference of each
patient with their actual behaviour. For this external validity test,
we only included patients diagnosed with PC who filled in the DCE
and had the opportunity to choose in real life between AS,
radiotherapy, and surgery (i.e., they had to make a treatment
choice relevant to that presented in the survey). The external
validity test was a simple straightforward test in which the stated
preference of each patient (i.e., the chosen alternative from the
choice set with three different treatment modalities) was directly
compared with their actual behaviour (i.e., the chosen PC
treatment in real life).
RESULTS
Respondents. The response rate to the questionnaire was 110 out
of 150 (73%) for patients and 50 out of 150 (33%) for urologists.
Patients had a mean age of 73 (s.d.¼ 2.2) years, one-third had a
higher educational level, they mainly lived together with a partner,
and 21% of the patients had PC (based on the biopsy result later
on; Table 2). Urologists had a mean age of 49 (s.d.¼ 8.3) years and
mainly worked in peripheral hospitals (Table 2).
Discrete choice experiment results. Of the 110 patients 97 (88%),
and of the 50 urologists 45 (90%) had no difficulty filling in the
DCE questionnaire. On an average, patients had a more negative
attitude towards radiotherapy and surgery than that towards AS
(Po0.01; Table 3). The estimated s.d. were significant, which
indicated stated preference heterogeneity among patients for PC
treatment modality. Besides the treatment modality (including the
one level attributes ‘risk of other permanent side effects due to
treatment’, ‘frequency of PSA testing’, and ‘treatment aim’), the
attribute ‘risk of urinary incontinence’ proved to influence patients’
stated preferences for PC treatment (Po0.01; Table 3). The
negative direction of this coefficient was consistent with our
hypotheses and showed, therefore, theoretical validity. One patient
characteristic had a significant influence on the stated preference
for treatment modality: anxious/depressed feelings. The positive
sign given to the interaction coefficient between patient character-
istic ‘anxious/depressed feelings’ and treatment modality indicated
that patients who had anxious/depressed feelings were more
expected to opt for radiotherapy (P¼ 0.05) or surgery (Po0.01)
than patients who did not have anxious/depressed feelings.
On average, urologists did not have a stated preference for
surgery, radiotherapy, or AS (P40.05; Table 3). However, the
estimated s.d. for surgery was significant, which indicated stated
preference heterogeneity among urologists for surgery as a PC
treatment alternative. The ‘risk of urine incontinence’ and ‘risk of
erectile dysfunction’ proved to influence urologists’ stated
preferences for PC treatment (Po0.05; Table 3), except for the
attribute ‘risk of erectile dysfunction due to surgery’. The negative
coefficients of these attributes were consistent with our a priori
hypotheses.
Predicted choice probabilities. The probability to choose for a
specific PC treatment (i.e., AS or radiotherapy with 5% risk of
permanent urinary incontinence and 25% risk of erectile dysfunc-
tion, or surgery with 20% risk of permanent urinary incontinence
and 45% risk of erectile dysfunction) showed a substantial
difference between the patient groups. Patients who had anxious/
depressed feelings based on responses to the EQ-5D had a higher
probability to opt for radical treatment than for AS (59% and 41%,
respectively; Table 4). In contrast, patients who did not have
anxious/depressed feelings had a lower probability to opt for
radical treatment than for AS (24% and 76%, respectively), which
was quite similar to the choice probabilities of urologists (23% for
radical treatment vs 77% for AS; Table 4).
Stated preferences vs real behaviour. Owing to patients’ and
tumour characteristics, only 10 out of 23 patients with PC (43%)
who filled in the DCE had the opportunity to choose in real life
between AS, radiotherapy, and surgery (i.e., they had to make a
treatment choice relevant to that presented in the survey). None of
these patients mentioned anxious/depressed feelings. The urologist
gave a treatment advice for 9 of these 10 patients after they filled in
the DCE questions; the advice given was AS. All 10 patients stated
in the DCE that they preferred AS. Indeed, 8 out of 10 chose AS,
whereas one patient underwent radiotherapy, and one patient
underwent surgery.
Table 2. Characteristics of respondents who filled in the discrete choice
experiment
Characteristics
Patients
(n¼110)
Urologists
(n¼50)
Age, years (mean±s.d.) 72.9±2.2 49.2±8.3
Sex (%)
Male 100 82
Female 0 18
Household (%)
Single 18 NA
With partner 82 NA
Educational level (%)
Low 31 0
Intermediate 39 0
High 31 100
Anxious/depressed feelings (%)
Yes 9 NA
No 91 NA
Prostate cancer (diagnosed two weeks after filling in the
DCE; %)
Yes 21 NA
No 79 NA
Hospital type (%)
University NA 22
Peripheral NA 78
Abbreviations: DCE¼discrete choice experiment; NA¼not applicable.
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DISCUSSION
Risk of urinary incontinence was an important determinant of
patients’ and urologists’ stated preferences for PC treatment. In
addition, treatment modality (including attributes as ‘frequency
of PSA testing’, ‘treatment aim’, and ‘risk of other permanent
side effects than urine and erectile problems’) also influenced
patients’ stated preferences, whereas risk of erectile dysfunction
due to radiotherapy mainly influenced urologists’ stated
preferences. Preference heterogeneity for treatment modality
was substantial for both patients and urologists. Both patients
and urologists had a higher choice probability for AS than that
for radical treatment (76% vs 24%, respectively and 77% vs 23%,
respectively), except for patients who had anxious/depressed
feelings. For this latter group, the choice probability for AS was
Table 3. Patients’ and urologists’ stated preferences for prostate cancer treatment based on a panel error component model
Patients Urologists
Attribute levels Coefficient 95% CI Coefficient 95% CI
Type of treatment
Active surveillance (ref level) 0 0
Radiotherapy Mean 5.33a (8.55 to 2.12)  1.62 ( 3.82 to 0.59)
s.d. 6.02a (3.65 to 8.38) 0.64 ( 0.85 to 2.13)
Surgery Mean 11.52a (16.97 to 6.06)  1.41 ( 4.59 to 1.77)
s.d. 10.23a (5.74 to 14.72) 2.53a (1.56 to 3.49)
Risk of urinary incontinence
Radiotherapy (per %) 0.18a (0.32 to 0.05)  0.21a ( 0.33 to  0.09)
Surgery (per %) 0.13a (0.17 to 0.08)  0.18a ( 0.24 to  0.13)
Risk of erectile dysfunction
Radiotherapy (per %) 0.01 (0.05 to 0.08)  0.04b ( 0.07 to 0.00)
Surgery (per %) 0.01 (0.04 to 0.03) 0.03 ( 0.01 to 0.07)
Anxious (yes)
Radiotherapy 5.60a (1.23 to 9.97) NA
Surgery 6.95a (2.48 to 11.42)
Abbreviations: CI¼ confidence interval; NA¼ not applicable; ref¼ reference. Dummy-coded variables used for ‘type of treatment’ (reference level¼ active surveillance) and ‘anxious’ (reference
level¼ having no anxious feelings); N¼ 976 observations (110 patients 9 choice sets 14 missing choices), and N¼ 541 observations (50 urologists 11 choice sets 9 missing choices).
aIndicates significance at the 1% level.
bIndicates significance at the 5%.
Table 4. Predicted choice probabilities for prostate cancer treatment alternatives based on the stated preferences of patients and urologists
Attributes Active surveillance Radiotherapy Surgery
Risk of permanent urinary
incontinency due to treatment (%)
0 5 20
Risk of permanent erectile dysfunction
due to treatment (%)
0 25 45
Risk of other permanent side effects
due to treatment
No Yes, substantial risk of bowel
problems and frequent urinate
Yes, small risk of mortality within
six weeks
Main aim is cure No, the tumour remains in the body Yes, but the disease may return Yes, but the disease may return
Frequency of PSA testing with a risk of
new prostate biopsies
Four times a year and at least one biopsy Once a year Once a year
Respondents P(A) P(B) P(C)
Patients with anxious/depressed
feelings
41% 38% 21%
Patients without anxious/depressed
feelings
76% 15% 10%
Urologists 77% 13% 11%
Abbreviations: P(A)¼probability to opt for active surveillance; P(B)¼probability to opt for radiotherapy; P(C)¼probability to opt for surgery; PSA¼prostate specific antigen.
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considerably lower than that for radical treatment (41% vs 59%,
respectively).
There are no previous DCEs investigating patients’ and
urologists’ stated preferences for PC treatment. However, one
review study investigated why patients with localised PC choose
one treatment in preference to another (Zeliadt et al, 2006); the
authors found that although patients stated that side effects are
important, few patients reported that side effect factors ultimately
influenced their treatment choice. These results are in line with the
findings in the present study, showing that urinary incontinence
as a side effect had a significant influence on patients’ stated
preferences for PC treatment, but also the treatment modality
per se (including attributes other than side effects). Our finding
that patients who had anxious/depressed feelings had a higher
probability to choose for radical treatment is in line with another
study (van Tol-Geerdink et al, 2006), which showed that patients
with higher anxiety/depressed feelings more often chose aggressive
treatment than patients with low anxiety/depressed feelings. Our
finding that the risk of erectile dysfunction lowered urologists’
stated preference for radiotherapy but not for surgery, suggests that
the urologists accept erectile dysfunction more as a consequence of
surgery than that of radiotherapy. This finding deserves further
research because other treatment alternatives are currently
available that have a lower risk of this side effect.
Several DCE studies have shown that patients and physicians
may differ substantially in their trade-offs between health-care
interventions (Bishop et al, 2004; Lee et al, 2005; Mantovani et al,
2005; de Bekker-Grob et al, 2009). By understanding factors that
influence patients’ treatment decisions, physicians may become
more sensitive to individual patients’ preferences/concerns, which
may have a positive effect on the process and outcomes of shared
decision making. Our study makes some contributions to such
understanding, on the basis of the fact that our study shows that, in
contrast to urologists, risk of erectile dysfunction due to radio-
therapy did not influence patients’ stated preferences, whereas the
treatment modality (including other side effects and non–side
effects) did. Nevertheless, to obtain more insight into the trade-offs
between attributes, conducting an unlabelled DCE may be
worthwhile (de Bekker-Grob et al, 2010; see the following
paragraph for details).
In contrast to commonly used unlabelled DCE studies in
health care, we used a labelled DCE design, as PC treatments may
evoke individual feelings that cannot be described in an
unlabelled DCE (e.g., a patient may have a strong preference
for AS because his neighbour had a positive experience with AS;
or an urologist may have some additional background knowledge).
Using a labelled DCE design, the PC alternatives were more
realistic and can take into account individual feelings/knowledge
for specific treatment modalities, which adds to the validity of the
results (de Bekker-Grob et al, 2010). However, this advantage of a
labelled DCE also has a disadvantage. As the PC treatment
alternatives described in our choice sets were very realistic, each
treatment modality had several fixed attribute levels (i.e., one fixed
attribute level for ‘risk of other side effects’, one fixed attribute level
for ‘frequency of PSA testing’, and one fixed attribute level for
‘treatment aim’). As a consequence, the value of each of these fixed
attribute levels were all captured in the alternative specific
constants. Therefore, insight into which attribute of the treatment
modality (i.e., risk of other side effects, frequency of PSA testing, or
treatment aim) was most important for the respondents, what
additional information respondents may have used in their
decision for a specific alternative label, and the trade-offs
respondents made between the attributes, is limited. To obtain
more insight into the reasons for the preference structure of
treatment modality and the alternative label, and to determine the
trade-offs between these treatment-specific attributes, further
research is needed.
The present study has several limitations. First, although a
response rate of 33% for physicians was similar to other DCE
studies (Ashcroft et al, 2006; Szeinbach et al, 2008), this response
rate is clearly suboptimal. We lacked information on the
experience level of the urologists in treating patients with early
PC and also a complete list of reasons for non-response. It is
possible that urologists who were open-minded towards treatments
other than surgery were more liable to participate in our study than
colleagues who were less open-minded. This might have an
influence on the outcome of the study, and might explain the lower
stated preference found for surgery compared with an earlier study
of Ramsey et al (2011). Second, the inclusion of rates in our DCE
might have caused problems with understanding the choice task;
however, 88% of the patients and 90% of the urologists stated that
they had no difficulty with the DCE questions. Third, we selected
the most relevant attributes using literature and expert interviews;
however, this careful procedure does not guarantee that attributes
that we did not include are irrelevant to urologists’ or patients’
(stated) preferences for PC treatment. Finally, although the
calculated choice probabilities based on DCE data of patients were
similar to the actual behaviour in PC treatment at an aggregate
level, additional insight might be obtained if reasons for differences
between the stated preferences of patients and their actual
behaviour in PC treatment could be investigated.
In conclusion, this study used DCE methodology to quantify the
stated preferences of patients and urologists for PC treatment.
Although patients and urologists generally may prefer similar
treatments for PC, they showed different trade-offs between
various treatment aspects. The implications are that urologists’
awareness of potential differences with the patient’s perspectives on
treatment decisions may improve the shared decision-making
process, which may avoid post-treatment decisional regret in
patients.
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APPENDIX I
Two examples of choice sets
Assume that both treatments for prostate cancer treatment are
equally effective regarding survival rate. Which treatment do you
prefer? (Please tick one box.)
Assume that both treatments for prostate cancer treatment are
equally effective regarding survival rate. Which treatment do you
prefer? (Please tick one box.)
APPENDIX II
A choice set presenting the most plausible attribute levels for three
prostate cancer treatment alternatives
Active Surveillance Radiotherapy Surgery
Risk of permanent 
urinary incontinence 
due to treatment 
Nobody (0%) 5 out of 100 (5%) 20 out of 100 (20%)
Risk of permanent 
erectile dysfunction 
due to treatment 
Nobody (0%) 25 out of 100 (25%) 45 out of 100 (45%)
Risk of other 
permanent side-effects 
due to treatment 
No
Yes, substantial risk of
• Bowel problems
• Frequent urge to 
urinate
Yes, small risk of
mortality within 6 
weeks
Main aim is cure No, the tumour remains 
in the body
Yes, but the disease 
may return 
Yes, but the disease 
may return 
Frequency of PSA 
testing with a risk of 
new prostate biopsies 
Four times in a year and 
at least one biopsy per 
year 
Once in a year Once in a year 
Which alternative do 
you prefer?
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